Sarcoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• JNK 0
• VEGF 3
• ERK 0
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• JAK 1
• PARP 4
• YAP 0
• EGFR 1
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• HIF-1 0
• PTEN 0
• EZH2 0
• GPX4 0
• PPAR 0
• NF1 5
• AMPK 0
• GPC3 5
• METTL3 1
• PDGFR 3
• ABL1 0
• COX-2 0
• ROS1 2
• AXL 0
• CD47 0
• CDKN2A 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• CXCR4 0
• FLT3 0
• FTO 0
• HDAC 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 27+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

  NCT03116529· University of Maryland, Baltimore· Updated 5 Nov 2026

  “Limited Accrual”Registry text, quoted unchanged. Source

• Terminated

  Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

  NCT02408861· National Cancer Institute (NCI)· Updated 21 Jan 2026

  “Inadequate accrual rate”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 40
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 184
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 152
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 194
• Machine Learning 28
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Biomineralized SERS Nanotags Encode Biomolecular Identity into Machine Learning-Resolvable Fingerprints.

  ACS Appl Mater Interfaces, Sept 2026

• Mapping high resolution, multidimensional phase diagrams of near-physiological protein condensates.

  Nat Commun, Sept 2026

• Development and Validation of an Interpretable Machine Learning Model for Predicting Early Pulmonary Metastasis Risk in Osteosarcoma.

  Cancer Med, Sept 2026

• Predicting gross-total resection in skull base chondrosarcoma: a multi-institutional machine learning study.

  J Neurosurg, Jul 2026

• Radiomics-based causal machine learning for exploratory treatment-effect estimation of neoadjuvant chemotherapy cycle intensity in osteosarcoma: a proof-of-concept study.

  BMC Med Imaging, Jun 2026

• Dual-parameter photoacoustic spectral analysis and machine learning for noninvasive monitoring of osteosarcoma treatment response.

  Ultrasonics, Jun 2026

• Enhancing Osteosarcoma Survival Predictions: A Comparative Study of a Multicomponent-Model Machine Learning Approach Integrating SEER and NCDB Data Sets Versus Conventional Single-Data-Set Modeling.

  J Bone Joint Surg Am, May 2026

• Predicting resistance to neoadjuvant chemotherapy in osteosarcoma using machine learning with clinical data and T2-weighted MRI radiomics.

  Eur Radiol Exp, May 2026

• Machine learning-based integrative analysis identifies CXCL13-driven tertiary lymphoid structures as favorable immune and prognostic features in osteosarcoma.

  Cell Oncol (Dordr), May 2026

• Multicentre MRI-based machine learning model for noninvasive prediction of pulmonary metastasis in osteosarcoma integrating intra-tumoral heterogeneity features.

  Eur J Radiol, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.